Enabling drug release from medical devices
PolyActiva Pty Ltd uses a unique drug-polymer conjugate technology to enable site specific drug delivery from medical device components, such as implants, films, or fibers.
**PRESS RELEASE: November 2020 – PolyActiva Pty Ltd, a clinical-stage Australian ophthalmology biopharmaceutical company, announced it has successfully completed its Phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant....read more…
The PolyActiva product portfolio is composed of market validated products at different stages of development and with different risk / reward profiles.
Preventive & Treatment Implants:
Sustained Drug Release & Fully Biodegradable
PolyActiva has developed a platform technology that enables the slow release, site-specific drug delivery directly to the site of action.